This is a multi-institution collaboration, led by Dr. Kathrin Bernt, Children’s Hospital of Philadelphia. The aims are 1) functional and epigenomic predictors of clinical response to venetoclax + induction in infants with newly diagnosed ALL and 2) effect of venetoclax + chemotherapy on T-cells from infants with ALL.